Search - tctmd.com

Displaying 1 - 20 of 41

Sort: Relevancy | Date

Effect of Intensive BP-Lowering on Cardiac Biomarkers Varies: SPRINT Analysis

News Daily News

Effect of Intensive BP-Lowering on Cardiac Biomarkers Varies: SPRINT Analysis

December 23, 2022

Reduction in BP Drives Treatment Preference for Hypertensive Patients

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

News Daily News

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

November 16, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

November 08, 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

Checking Cumulative High BP Exposure Hones CV Risk Prediction in Diabetes

News Daily News

Checking Cumulative High BP Exposure Hones CV Risk Prediction in Diabetes

September 14, 2022

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection Open With no difference between nighttime and morning dosing, “patients can take their tablets whenever it’s convenient.” configuration options With no difference between nighttime and morning dosing, “patients can take their tablets whenever it’s convenient.”

News Conference News ESC 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection

August 26, 2022

New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill

News Daily News

New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill

August 23, 2022

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.